Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05368467

National Registry and Cohort Study of Pulmonary Vascular Disease

This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with PH；also to set up registration system of PH in China, to build a database of Chinese PH, to establish a web-based international standard data acquisition system for PH and a multicenter clinical research platform. The results of the study will provide a basis for the future national health policy for prevention and treatment of PH.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pulmonary Arterial Hypertension Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed or previously diagnosed patients with PH.
  • Documentation of mean pulmonary arterial pressure (mPAP) >20 mm Hg by right heart catheterization, performed at any time prior to study enrollment.

Exclusion criteria

  • Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH.
  • Do not meet the required hemodynamic criteria for entry into the study.

Treatment and study plan

The clinical course and disease management

Combination Product

The clinical course and disease management of pulmonary hypertension patients

Primary outcomes

  1. All-cause Death

    Time frame: 5 years

Secondary outcomes

  1. Number of Participants with Clinical Worsening

    Time frame: 5 years

    Clinical worsening during follow-up was defined as worsening PAH or atrial septostomy or listing for lung transplantation or all-cause death. Worsening PAH required the presence of worsening PAH symptoms and a decrease in 6-minute walk distance greater than 15% from baseline and the requirement for additional PAH treatments (all three conditions had to be present).

Study contacts

Contact information is provided by the study sponsor or research team.

Jing Kan, MPH

CONTACT

[email protected]

+86-25-52271398

Shao-Liang Chen, MD, PhD

CONTACT

[email protected]

+86-25-52271351

Sponsors and collaborators

Lead sponsor

Nanjing First Hospital, Nanjing Medical University

Other

Registry information

Acronym: NCPVD

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
May 10, 2022
Registry last updated
Jun 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.